ICH Q12 Guidance and Emerging Technology Program (11of16) Generic Drugs Forum 2020

Автор: U.S. Food and Drug Administration

Загружено: 2020-05-01

Просмотров: 4033

Описание: Ashley Boam and Thomas O’Connor from CDER’s Office of Pharmaceutical Quality discuss ICH Q12 as it applies to generic drugs and CDER’s emerging technology program.

Learn more at https://www.fda.gov/drugs/news-events...

_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Upcoming training and free continuing education credits: https://www.fda.gov/cdersbia

CDER SBIA 2020 Playlist:    • 2020 CDER Small Business and Industry Assi...
LinkedIn:   / cder-small-business-and-industry-assistance
Training resources: https://www.fda.gov/cderbsbialearn

Twitter:   / fda_drug_info

CDER small business e-mail update subscription: https://updates.fda.gov/subscriptionm...

Email: [email protected]
Phone: (301) 796-6707 I (866) 405-5367

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...

ICH Q12 Guidance and Emerging Technology Program (11of16) Generic Drugs Forum 2020

Доступные форматы для скачивания:

Скачать видео

Информация по загрузке:

Скачать аудио

Похожие видео

Common CMC (Quality) Issues and How to Avoid Them Part I (12of16) Generic Drugs Forum

Common CMC (Quality) Issues and How to Avoid Them Part I (12of16) Generic Drugs Forum

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

Learn About ClinicalTrials.gov Modernization and How to Provide Input – Mar. 6, 2020

Learn About ClinicalTrials.gov Modernization and How to Provide Input – Mar. 6, 2020

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

SEND for CBER, What You Need to Know

SEND for CBER, What You Need to Know

FDA Direct: Combating Rare Diseases at the FDA

FDA Direct: Combating Rare Diseases at the FDA

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

Change Management: ICH Q12 and Established Conditions (12of33) Quality – Oct. 16-17, 2019

Change Management: ICH Q12 and Established Conditions (12of33) Quality – Oct. 16-17, 2019

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA Direct: Combating Rare Diseases at the FDA

FDA Direct: Combating Rare Diseases at the FDA

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA-MHRA-HC 2024 Joint Symposium (Day 1)

FDA-MHRA-HC 2024 Joint Symposium (Day 1)

Process Validation and ICH Q7

Process Validation and ICH Q7

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

Regulatory Considerations for Impurity Qualification: ICH Q3A/Q3C/Q3D, RLD & MDD

Regulatory Considerations for Impurity Qualification: ICH Q3A/Q3C/Q3D, RLD & MDD